Improved patient satisfaction and pain evolution with almotriptan in migraine: A primary care study

Current Medical Research and Opinion

Volumn 27, Issue 3, 2011, Pages 559-567

  Díaz Insa, Samuel ^a   Vila, Carlos ^b   McGown, Caroline C ^c  

^a HOSPITAL FRANCESC DE BORJA   (Spain)

^b Almirall SA ^*  (Spain)

^c ContentEdNet ^*  (Spain)

Author keywords

Almotriptan; Early intervention; Migraine; Patient satisfaction; Triptans

Indexed keywords

ALMOTRIPTAN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PROPHYLAXIS; TREATMENT DURATION; TREATMENT RESPONSE;

ANALGESICS; CHEMOPREVENTION; DISEASE PROGRESSION; HUMANS; MIGRAINE DISORDERS; PAIN; PATIENT SATISFACTION; PRIMARY HEALTH CARE; PROGNOSIS; TRYPTAMINES;

EID: 79951629441     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.545815     Document Type: Article

References (44)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine- current understanding and treatment. N Engl J Med 2002;346:257-70
2. Menken M, Munsat TL, Toole JF. The global burden of disease study- implications for neurology. Arch Neurol 2000;57:418-20 (Pubitemid 30140537)
3. Silberstein SD. Preventive migraine treatment. Neurol Clin 2009;27:429-43
4. Fumal A, Schoenen J. Current migraine management- patient acceptability and future approaches. Neuropsychiatr Dis Treat 2008;4:1043-57
5. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 2006;13:560-72 (Pubitemid 43873628)
6. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007;27:394-402 (Pubitemid 46632598)
7. Goadsby PJ. Sprenger T. Migraine pathogenesis and state of pharmacological treatment options. BMC Med 2009;7:71
8. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58 (Pubitemid 36609333)
9. Welch KMA, Mathew NT, Stone P, et al. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000;20:687-94
10. Humphrey PPA, Feniuk W, Perren MJ, et al. Serotonin and migraine. Ann NY Acad Sci 1990;600:587-98
11. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med 1993;44:145-54 (Pubitemid 23117855)
12. Goadsby PJ. The pathophysiology of headache. In: Silberstein SD, Lipton RB, Soloman S, eds. Wolff's Headache and Other Head Pain, 7th edn. Oxford: Oxford University Press, 2001:57-72
13. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008;28:383-91 (Pubitemid 351341454)
14. Tfelt-Hansen P, Saxana PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000;123:9-18 (Pubitemid 30037964)
15. Bou J, Gras J, Cortijo J, Morcillo EJ, et al. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 2001;21:804-12 (Pubitemid 34621525)
16. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acuste treatment of multiple migraine attacks: results of a large randomized, double-blind placebo-controlled study. Cephalalgia 2000; 20:588-96 (Pubitemid 32269479)
17. Deleu D, Hanssens Y. Current and emerging second-generation triptans in acute migraine therapy: a comparative review. J Clin Pharmacol 2000;40: 687-700
18. Creac'h C, Radat F, Mick G, et al One or several types of triptan overuse headaches? Headache 2009 49 519-28.
19. Goadsby PJ. The 'Act when mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia 2008;28:36-41
20. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991;31:295-9
21. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765-86 (Pubitemid 32154559)
22. Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000;40:792-7 (Pubitemid 32053239)
23. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000;22:1035-48
24. Linde M, Mellberg A, Dahlof C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia 2006;26:712-21
25. Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT® Early Migraine Intervention Study). Headache 2007;47:189-98
26. Lucas C, Geraud G, Valade D, et al. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 2006;46:715-25
27. Shapero G, Dowson A, Lacoste JP, et al. Improved migraine management in primary care: results of a patient treatment experience study using zolmitrip-tan orally disintegrating tablet. In J Clin Pract 2006;60:1530-5 (Pubitemid 44742147)
28. Lanteri-Minet M, Diaz-Insa S, Leone M, et al. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int J Clin Pract 2010;64:936-43
29. [IHS 2004] Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edn. Cephalalgia 2004;24:1-160
30. Geraud G, Lanteri-Minet M, Lucas C. on behalf of the French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004;26:1305-18
31. Pointer JS. A novel visual analogue scale (VAS) device: an instrument based on the VAS designed to quantify the subjective visual experience. Ophthal Physiol Opt 2004;24:181-5 (Pubitemid 41711015)
32. Colman SS, Brod MI, Krishnamurthy A, et al. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001;23:127-45 (Pubitemid 32113627)
33. Lá inez MJA, Galván J, Heras J, et al Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007 14 269-75 (Pubitemid 46384856)
34. Massiou H, Pradalier A, Donnet A, et al. Evaluation of efficacy, tolerability and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. Eur Neurol 2006;55:198-203
35. Diener HC, Dodick DW, Goadsby PJ, et al. Identification of negative predictors of pain0free response to triptans. Analysis of the eletriptan database. Cephalalgia 2007;28:35-40 (Pubitemid 350212650)
36. Mondell BE. A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine. Clin Ther 2003;25:331-41 (Pubitemid 36286908)
37. Pascual J, Diener HC. Use of almotriptan in triptan-experiences and triptan-na¿ve patients. Curr Med Res Opin 2007;23:2433-40 (Pubitemid 350033445)
38. Christoph-Diener H, Ferrari M, Mansbach H. Predicting the response to suma-triptan: the sumatriptan naratritan aggregate patient database. Neurology 2004;63:520-4 (Pubitemid 39031384)
39. Gracia-Naya M, Alarcia-Alejos R, Modrego-Pardo PJ. The importance of chronic migraine in a general neurology service. Rev Neurol 2008; 46:577-81 (Pubitemid 351767868)
40. Vincent MB, de Carvalho JJ. Primary headache care delivery by nonspecialists in Brazil. Brazilian Headache Care Cooperative Group. Cephalalgia 1999; 19:520-4 (Pubitemid 29309043)
41. Allais G, Acuto G, Cabarrocas X, et al. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci 2006;27:S193-7 (Pubitemid 44390141)
42. Allais G, Bussone G, De Lorenzo C, et al. Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects. Neurol Sci 2005;26:S125-9 (Pubitemid 40796496)
43. Martin VT. Menstrual migraine: a review of prophylactic therapies. Curr Pain Headache Rep 2004;8:229-37 (Pubitemid 38915110)
44. Ng-Mak DS, Cady R, Chen YT, et al. Can migraineurs accurately identify their headaches as 'migraine' at attack onset? Headache 2007;47:645-53 (Pubitemid 46733714)